Levoketoconazole
FDA-approved product (tablet, oral), marketed as Recorlev.
- Registered studies
- 6
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Adrenal gland disease
- Adrenal gland hyperfunction
- Cushing syndrome
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Anticorticosteroids
- FDA pharmacologic class
- Cortisol Synthesis Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis81.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
6registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Levoketoconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Tubocurarine ChlorideExisting use: Curare alkaloids51.4% AI-predicted activityagainst E. coliNo documented evidence found
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more51.4% AI-predicted activityagainst E. coli50+ registered studies
- BrigatinibExisting use: Neoplasm, Non-small cell lung carcinoma51.2% AI-predicted activityagainst E. coli48 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more51.1% AI-predicted activityagainst E. coli50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more51.0% AI-predicted activityagainst E. coli50+ registered studies
- EntrectinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma50.9% AI-predicted activityagainst E. coli46 registered studies
- DasatinibExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more50.8% AI-predicted activityagainst E. coli50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more50.5% AI-predicted activityagainst E. coli35 registered studies
- IvosidenibExisting use: Acute myeloid leukemia, Cholangiocarcinoma50.4% AI-predicted activityagainst E. coli50+ registered studies
- Thiamine HydrochlorideExisting use: Anemia (phenotype), Chronic kidney disease, Encephalopathy and 2 more50.4% AI-predicted activityagainst E. coli50+ registered studies
- VibegronExisting use: Overactive bladder, Polyuria, Urgency urinary incontinence and 1 more50.4% AI-predicted activityagainst E. coli16 registered studies
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma50.3% AI-predicted activityagainst E. coli3 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Bioavailability of Levoketoconazole and Ketoconazole Tablets
NCT04212000 · start 2019-12-16
Registered record
- Registry ID
- NCT04212000
- Conditions
- Healthy
- Interventions
- Levoketoconazole; Ketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2019-12-16
- Completion
- 2020-01-23
- Enrolment
- 34
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionLevoketoconazole; KetoconazolePhasePhase 1Registry statusCompletedDrug Interaction Study of Levoketoconazole and Metformin
NCT03880825 · start 2019-03-28
Registered record
- Registry ID
- NCT03880825
- Conditions
- Healthy Subjects
- Interventions
- Metformin 500 mg Oral Tablet; Levoketoconazole 150 - 600 mg (BID)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2019-03-28
- Completion
- 2019-05-03
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionMetformin 500 mg Oral Tablet; Levoketoconazole 150 - 600 mg (BID)PhasePhase 1Registry statusCompletedOpen-label Treatment in Cushing's Syndrome
NCT03621280 · start 2019-01-07
Registered record
- Registry ID
- NCT03621280
- Conditions
- Cushing Syndrome; Cushing Disease
- Interventions
- Levoketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2019-01-07
- Completion
- 2022-12-31
- Enrolment
- 51
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCushing Syndrome; Cushing DiseaseInterventionLevoketoconazolePhasePhase 3Registry statusCompletedLevoketoconazole Food Effect Study in Healthy Subjects
NCT03768388 · start 2018-11-30
Registered record
- Registry ID
- NCT03768388
- Conditions
- Healthy Subjects
- Interventions
- levoketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2018-11-30
- Completion
- 2018-12-24
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionlevoketoconazolePhasePhase 1Registry statusCompletedA Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
NCT03277690 · start 2017-09-26
Registered record
- Registry ID
- NCT03277690
- Conditions
- Endogenous Cushing's Syndrome
- Interventions
- Levoketoconazole; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-09-26
- Completion
- 2020-08-31
- Enrolment
- 84
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndogenous Cushing's SyndromeInterventionLevoketoconazole; PlaceboPhasePhase 3Registry statusCompletedTreatment for Endogenous Cushing's Syndrome
NCT01838551 · start 2014-08
Registered record
- Registry ID
- NCT01838551
- Conditions
- Endogenous Cushing's Syndrome
- Interventions
- Levoketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-08
- Completion
- 2018-11
- Enrolment
- 94
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndogenous Cushing's SyndromeInterventionLevoketoconazolePhasePhase 3Registry statusCompleted